INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Martin van den Bent; M Eoli; JM Sepulveda; Marion Smits; A Walenkamp; J S Frenel; E Franceschi; PM Clement; O Chinot; F Vos; N Whenham; P Sanghera; M Weller; Erik jan Dubbink; Pim French; J Looman; D Dey; S Krause; P Ansell; S Nuyens; M Spruyt; J Brilhante; C Coens; T Gorlia; V Golfinopoulos

doi:10.1093/neuonc/noz222

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Martin van den Bent
, M Eoli
, JM Sepulveda
, Marion Smits
, A Walenkamp
, J S Frenel
, E Franceschi
, PM Clement
, O Chinot
, F Vos
, N Whenham
, P Sanghera
, M Weller
, Erik jan Dubbink
, Pim French
, J Looman
, D Dey
, S Krause
, P Ansell
, S Nuyens

M Spruyt, J Brilhante, C Coens, T Gorlia, V Golfinopoulos

Research output: Contribution to journal › Article › Academic › peer-review

157 Citations (Scopus)

45 Downloads (Pure)

Original language	English
Pages (from-to)	684-693
Number of pages	10
Journal	Neuro-Oncology
Volume	22
Issue number	5
DOIs	https://doi.org/10.1093/neuonc/noz222
Publication status	Published - 2020

Research programs

EMC MM-03-24-01
EMC MM-03-44-06
EMC NIHES-03-30-02

Access to Document

10.1093/neuonc/noz222

Repub_127097_O-A.pdfFinal published version, 314 KB

Cite this

van den Bent, M., Eoli, M., Sepulveda, JM., Smits, M., Walenkamp, A., Frenel, J. S., Franceschi, E., Clement, PM., Chinot, O., Vos, F., Whenham, N., Sanghera, P., Weller, M., Dubbink, E. J., French, P., Looman, J., Dey, D., Krause, S., Ansell, P., ... Golfinopoulos, V. (2020). INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro-Oncology, 22(5), 684-693. https://doi.org/10.1093/neuonc/noz222

@article{bcde2f10c9e547baa849d94f9434554d,

title = "INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma",

author = "\{van den Bent\}, Martin and M Eoli and JM Sepulveda and Marion Smits and A Walenkamp and Frenel, \{J S\} and E Franceschi and PM Clement and O Chinot and F Vos and N Whenham and P Sanghera and M Weller and Dubbink, \{Erik jan\} and Pim French and J Looman and D Dey and S Krause and P Ansell and S Nuyens and M Spruyt and J Brilhante and C Coens and T Gorlia and V Golfinopoulos",

year = "2020",

doi = "10.1093/neuonc/noz222",

language = "English",

volume = "22",

pages = "684--693",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "5",

}

van den Bent, M, Eoli, M, Sepulveda, JM, Smits, M, Walenkamp, A, Frenel, JS, Franceschi, E, Clement, PM, Chinot, O, Vos, F, Whenham, N, Sanghera, P, Weller, M, Dubbink, EJ , French, P, Looman, J, Dey, D, Krause, S, Ansell, P, Nuyens, S, Spruyt, M, Brilhante, J, Coens, C, Gorlia, T & Golfinopoulos, V 2020, 'INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma', Neuro-Oncology, vol. 22, no. 5, pp. 684-693. https://doi.org/10.1093/neuonc/noz222

TY - JOUR

T1 - INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

AU - van den Bent, Martin

AU - Eoli, M

AU - Sepulveda, JM

AU - Smits, Marion

AU - Walenkamp, A

AU - Frenel, J S

AU - Franceschi, E

AU - Clement, PM

AU - Chinot, O

AU - Vos, F

AU - Whenham, N

AU - Sanghera, P

AU - Weller, M

AU - Dubbink, Erik jan

AU - French, Pim

AU - Looman, J

AU - Dey, D

AU - Krause, S

AU - Ansell, P

AU - Nuyens, S

AU - Spruyt, M

AU - Brilhante, J

AU - Coens, C

AU - Gorlia, T

AU - Golfinopoulos, V

PY - 2020

Y1 - 2020

U2 - 10.1093/neuonc/noz222

DO - 10.1093/neuonc/noz222

M3 - Article

C2 - 31747009

SN - 1522-8517

VL - 22

SP - 684

EP - 693

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - 5

ER -